Clinical Trials Browser

danvatirsen × Clear all

Carcinoma, Non-Small-Cell Lung

NCT05814666 2026-01-30

PEMDA-HN

Phase 2 Terminated

69 enrolled 21 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02546661 2025-12-29

BISCAY

Phase 1 Active not recruiting

117 enrolled

Genitourinary

Muscle Invasive Bladder Cancer

NCT03334617 2025-10-27

HUDSON

Phase 2 Active not recruiting

528 enrolled 16 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02983578 2025-05-06

Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

Phase 2 Active not recruiting

39 enrolled

GastrointestinalThoracic

Turcot syndrome, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03421353 2024-08-21

AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer

Phase 1 Completed

76 enrolled

Other solid neoplasm

Advanced Solid Tumours

NCT03527147 2022-08-15

PRISM

Phase 1 Completed

30 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03394144 2019-06-24

Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies

Phase 1 Completed

11 enrolled

Advanced Solid Malignancies

NCT02549651 2019-02-27

MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

Phase 1 Completed

32 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02417753 2017-05-15

AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites

Phase 2 Terminated

1 enrolled 10 charts

GastrointestinalGynecologic

Ascites, Gastrointestinal Neoplasms, Ovarian Neoplasms

NCT01839604 2017-03-06

A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma

Phase 1 Completed

58 enrolled 13 charts

Gastrointestinal

Carcinoma, Hepatocellular

Clinical Trials

MAGELLAN

PEMDA-HN

BISCAY

HUDSON

Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer

PRISM

Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies

MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites

A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma